Novavax Inc. NVAX reported positive results from three vaccine trials on Tuesday, one targeting both COVID and flu, one for stand-alone flu and one a high-dose COVID vaccine. All three candidates produced robust immune response in Phase 2 trials and showed a reassuring preliminary safety profile, said Novavax. “The stand-alone influenza vaccine candidate achieved statistically significant hemagglutination inhibition (HAI) antibody responses 31 to 56% higher for all four strains compared to Fluad,” said the company. The highest-dose stand-alone COVID vaccine achieved statistically significant neutralization responses that…
This article was originally published by Marketwatch.com. Read the original article here.
